Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038236 | 0.98 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL18631797 | 0.84 | NAAA (0.47) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL17749209 | 0.83 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL32688325 | 0.83 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL28260895 | 0.83 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL3011295 | 0.83 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL7519579 | 0.83 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL3394431 | 0.82 | NAAA (0.43) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL31169661 | 0.81 | NAAA (0.41) | NAAATSHRCES2EPHX1LPAR3 | |
| Hydrochloric Acid SCHEMBL6139986 | 0.81 | NAAA (0.41) | NAAATSHRALDH1A1CES2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307237-B9 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1307237-B1 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | NAAA 2306/4885TSHR 265/4885ALDH1A1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.